Details of the Drug

General Information of Drug (ID: DMXTCE7)

Drug Name
Carvedilol
Synonyms Coreg; Dilatrend; Eucardic; Carvedilolum [Latin]; BM 14190; Carvedilolum; SKF 105517; BM-14190; Coreg CR; DQ 2466; HSDB 7044; DQ-2466
Indication
Disease Entry ICD 11 Status REF
Congestive heart failure BD10 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [2]
Therapeutic Class
Antiviral Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 406.5
Topological Polar Surface Area (xlogp) 4.2
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Bioavailability
The bioavailability of drug is 6.3-18.4% [3]
Clearance
The clearance of drug is 500-700 mL/min [4]
Elimination
16% of carvedilol is excreted in the urine with <2% excreted as unmetabolized drug, and Carvedilol is primarily excreted in the bile and feces [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 - 10 hours [4]
Metabolism
The drug is metabolized via the CYP2D6, CYP1A2, or CYP1A1 to form 1-hydroxypheylcarvedilol [5]
Vd
The volume of distribution (Vd) of drug is 1.5-2 L/kg or 115 L [4]
Chemical Identifiers
Formula
C24H26N2O4
IUPAC Name
1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
Canonical SMILES
COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
InChI
InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
InChIKey
OGHNVEJMJSYVRP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2585
ChEBI ID
CHEBI:3441
CAS Number
72956-09-3
DrugBank ID
DB01136
TTD ID
D0D1HH
ACDINA ID
D00103

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HUAMN alpha-1 adrenergic receptor (ADRA1) TTDBOI7 ADA1A_HUMAN; ADA1B_HUMAN; ADA1D_HUMAN Inhibitor [6]
HUMAN beta adrenergic receptor (BAR) TTJB8UY ADRB1_HUMAN; ADRB2_HUMAN; ADRB3_HUMAN Antagonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 078332.
2 Can beta-adrenergic blockers be used in the treatment of COVID-19 Med Hypotheses. 2020 May 5;142:109809.
3 Sullivan HR, Billings RE, McMahon RE: Metabolism of cephalexin-14C in mice and in rats. J Antibiot (Tokyo). 1969 May;22(5):195-200.
4 Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994 May;26(5):335-46. doi: 10.2165/00003088-199426050-00002.
5 Wang T, Ueda Y, Zhang Z, Yin Z, Matiskella J, Pearce BC, Yang Z, Zheng M, Parker DD, Yamanaka GA, Gong YF, Ho HT, Colonno RJ, Langley DR, Lin PF, Meanwell NA, Kadow JF: Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir. J Med Chem. 2018 Jul 26;61(14):6308-6327. doi: 10.1021/acs.jmedchem.8b00759. Epub 2018 Jul 13.
6 Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J Am Coll Cardiol. 2003 Jan 15;41(2):340-5.